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Abstract Two virus-inducible transcription factors, IRF-1 and 
IRF-2 have been identified as an activator and a repressor, re- 
spectively, of the type I interferon (IFN) genes. Recent studies 
with mice carrying null mutations for the IRF-I or IRF-2 alleles 
have revealed the existence of IRF-l-dependent and -independent 
pathways mediating IFN-~ gene induction. Here we report that 
the expression of an IRF family member ISGF33, is induced upon 
viral infection in IRF- I - I - ,  IRF-2-1- embryonic fibroblasts. 
Furthermore, ISGF3y can bind to a virus-inducible promoter 
element in the IFN-/] gene. These results suggest hat ISGF33, 
or complex containing ISGF3y is involved in the IRF-l-independ- 
ent pathway mediating IFN-I~ gene regulation. 
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1. Introduction 
Interferons (IFNs) are pleiotropic cytokines that possess ev- 
eral biological activities, uch as anti-viral and anti-proliferative 
actions, on a variety of target cells [1,2]. Expression of the genes 
for type I (IFN<z, -fl) and type II (IFN-~,) IFN is regulated 
primarily at the transcriptional level [3-5]. Type I IFN genes 
are efficiently induced in a variety of cell types upon viral 
infection or treatment by double-stranded RNA, whereas the 
expression of type II IFN, i.e. IFN-y is restricted to mitogen- 
activated T lymphocytes [1,2]. 
During the course of our study on the regulation of the 
IFN-fl gene expression, two transcription factors, termed IRF- 
1 (IFN regulatory factor-l) and IRF-2 were isolated [6,7]. The 
IRF-1 and IRF-2 genes are induced by virus and IFNs [7]. 
IRF-1 and IRF-2 each binds to the same DNA sequence le- 
ments (IRF-Es) found within the virus-inducible promoters of 
the type I IFN genes and the ISREs (IFN stimulated response 
elements) of IFN-inducible genes [7,8]. A series of transfec- 
tion studies showed that IRF-1 can activate type I IFN and 
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IFN-inducible genes and that IRF-2 represses the action of 
IRF-1 [7,9-11]. 
As an approach to study further the role of IRFs in the 
regulation of the IFN system, we generated mice which lack 
functional IRF-1 and/or IRF-2 using gene disruption technol- 
ogy [12-14]. We have shown that induction of IFN-fl mRNA 
by double-stranded RNA, poly(rI):poly(rC), is markedly re- 
duced in embryonic fibroblasts (EFs) from IRF-l-deficient 
mice, as compared to EFs from wild type animals. On the other 
hand, IFN-fl mRNA expression levels were similar in mutant 
and wild-type EFs following induction by Newcastle disease 
virus (NDV). These results indicate the existence of IRF-1- 
dependent and -independent pathways of IFN-fl gene induction 
[12]. Thus, in addition to IRF-1, other transcription factor(s) 
must be acting upon the virus-inducible elements. 
Besides IRF-1 and IRF-2, two other factors, ISGF3y (IFN 
stimulated gene factor 3y) and ICSBP (IFN consensus e- 
quence binding protein) have been found whose amino terminal 
sequences are highly homologous to those found in the amino 
terminal regions of the IRFs. This region has been shown to 
be the DNA binding domain [15,16], and these factors have 
been designated as members of the 'IRF-family' [16]. ISGF3~" 
was found to be the DNA binding subunit of a trimeric omplex 
containing two other proteins, STAT1 and STAT2. This com- 
plex, termed ISGF3, is found upon cellular stimulation by type 
I IFNs. ISGF3 in turn participates in the transcriptional activa- 
tion of IFN-inducible genes by binding to the ISRE [17]. ICSBP 
also binds to similar DNA sequence lements, however, the 
expression of ICSBP is restricted to cells of lymphoid and 
macrophage lineages [15]. 
In the present study, we report our findings on the potential 
role of ISGF37 in IFN-fl gene regulation. First, we demon- 
strate that the expression of ISGF3y mRNA is induced by 
NDV and that this induction correlates with the induction of 
IFN-fl mRNA in cells which lack both IRF-1 and IRF-2. We 
also show that ISGF3y by itself binds to the virus-inducible 
element of the IFN-fl promoter, although the binding of the 
larger ISGF3 complex to the element is weak, if occurring at 
all. Furthermore, the binding affinity of ISGF3y is decreased 
when mutations which cause reduced NDV inducibility are 
introduced into the IFN-fl promoter sequences. These results 
suggest that ISGF3y participates in the regulation of the tran- 
scription of the IFN-fl gene in response to viral infection. 
2. Materials and methods 
2.1. Cellculture 
The IRF-1-/- and IRF-2-/- mice used in this study have been 
previously described [12]. The method of isolation and culture of mouse 
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primary EFs were as described [13,14]. HeLa cells were maintained in
Dulbecco's modified Eagle's medium supplemented with 10% fetal bo- 
vine serum. NDV infection was performed as previously [18]. 
2.2. Preparation and screening of cDNA library 
Total RNA was prepared from EFs derived from mice deficient for 
both IRF-I and IRF-2 genes (IRF-dKO EFs) [13,14] 8 hours after 
NDV infection. Poly(A) + RNA was purified using mRNA Purification 
Kit (Pharmacia). cDNA was synthesized from the poly(A) ÷ RNA using 
random hexanucleotides a primers. To prepare the cDNA library, the 
cDNA was cloned into the 2gtl 1 vector (Stratagene). To clone the 
murine ISGF37 cDNA, the library was screened using a 32p-labeled 
DNA probe containing a part of the sequence of murine ISGF3y 
obtained by the polymerase chain reaction (see below). 
2.3. Polymerase chain reaction (PCR) and sequencing 
The cDNA mentioned above was used as the template. Primers used 
were as follows; sense primer, ATICCITGGAA(A/G)CA(T/C)GC, an- 
tisense primer, GCACAICGTA(A/G)IC(G/T)IGT(T/C)TTCCA PCR 
was performed for 30 cycles with the conditions; 94°C 30 s (denatura- 
tion), 37°C 60 s (annealing), 72°C 60 s (extension). 
PCR products were subcloned into the pCRII vector (Invitrogen) 
and sequenced via a dideoxy method (Sequenase, USB). 
2.4. RNA blotting analysis 
The procedure for RNA blotting analysis was as previously described 
[10]. The probe for the IFN-fl mRNA was prepared as described [6]. 
The probe for the murine ISGF37 mRNA was prepared from a 165 bp 
EcoRI fragment of the pCRII vector containing the ISGF37 PCR 
product. The probes were labeled with [0>3/p]dCTP by the random 
prime method (Amersham). 
2.5. Electrophoretic gel mobility shift analysis (EMSA) 
The binding reaction for EMSA was performed as previously de- 
scribed [10]. The samples were then resolved on 4.8% polyacrylamide 
gels run in TBE buffer [19]. 
The double-stranded oligonucleotide probes used in the assays were 
as follows, 
IFN-fl (-95 to -54 [18]); 
GACATAGGAAAACTGAAAGGGAGAAGTGAAAGTGGGAAATTCCTCT 
ATCCTTTTGACTTTCCCTCTTCACTTTCACCCTTTAAGGAGACTTA 
IFN-fl (-95 to -63 [18]); 
GACATAGGAAAACTGAAAGGGAGAAGTGAAAGTGGG 
ATCCTTTTGACTTTCCCTCTTCACTTTCACCCTTTA 
ISRE (from human 2'-5' oligoA synthetase; -104 to -83 [20]); 
AGCTTCTGAGGAAACGAAACCAACAG 
AGACTCCTTTGCTTTGGTTGTCCTAG 
Probes were labeled with [T-32p]ATP using T4 polynucleotide kinase. 
Protein sources were prepared as follows. The full-length uman 
ISGF3y cDNA (clone 38-1) cloned into pBluescript SK(+) [16] was 
transcribed using T7 RNA polymerase (Stratagene). The full-length 
human IRF-1 cRNA was prepared as described [21]. The RNAs were 
subjected to in vitro translation with rabbit reticulocyte lysate (Amer- 
sham). The procedure for preparing whole cell extracts was as described 
[10]. 
Anti-ISGF37 serum was as described [16]. Anti-IRF-1 and anti-IRF- 
2 sera were as described [11] 
3. Results 
3.1. Correlation of lSGF37 and IFN-fl mRNA expression upon 
viral infection 
As an approach to identify a factor(s) involved in the IRF- 
1-independent i duction of IFN-fl gene expression, we utilized 
cells from mice lacking the expression of both IRFs [13,14], 
thus allowing us to search for a factor(s) that is active in the 
absence of IRF-1 and IRF-2. The IRF-dKO EFs expressed 
IFN-fl mRNA upon NDV infection (see Fig. 2). The induction 
kinetics, as well as the expression level of the IFN-fl mRNA in 
the IRF-dKO EFs was indistinguishable from those of IRF-1- 
deficient EFs from a littermate animal (data not shown), indi- 
cating that a similar IRF- l - independent pathway is at work in 
both the IRF-dKO EFs and IRF-l-deficient EFs. 
We initially hypothesized that the putative factor(s) involved 
in the IRF-l- independent pathway may belong to the IRF- 
family, and that such a factor would compensate for the action 
of IRF-1 on the IRF-Es in the IFN-fl gene promoter. We 
attempted to clone this candidate factor(s) by PCR amplifica- 
tion of cDNA prepared from IRF-dKO EFs during the peak 
of IFN-fl gene expression following NDV infection. For prim- 
ers, we used a set of degenerate synthetic oligonucleotides 
whose sequence was inferred from the amino acid sequences of 
the conserved IRF-family DNA binding domain [16] (see sec- 
tion 2). The PCR produced a single fragment of the size pre- 
dicted from the known IRF-family members. The products 
were subcloned into an appropriate vector and sequenced. The 
nucleotide sequence of all 33 clones analyzed was identical, and 
the deduced amino acid sequence resembled that of human 
ISGF37. To confirm that these PCR products were derived 
from the murine homologue of ISGF3y, we cloned the 5' up- 
stream nucleotide sequences by screening a cDNA library with 
the PCR product as a probe. The predicted amino acid se- 
quences of these upstream sequences were again found to be 
homologous to human ISGF3z (Fig. 1). In fact, a 90% homol- 
ogy in amino acids 1-87 exists between murine and human 
ISGF37. These observations indicate that the clones obtained 
by PCR did indeed correspond to murine ISGF37 and raised 
the possibility that ISGF3y, which is known to function in the 
regulation of IFN-inducible genes, may also contribute to the 
regulation of the IFN-fl gene. 
To examine this possibility, we first analyzed the expression 
of the ISGF3y and IFN-fl mRNAs in IRF-dKO EFs during the 
course of viral infection by RNA blotting analysis. As shown 
in Fig. 2A, the expression of ISGF37 mRNA was increased 
after NDV infection. This increase in ISGF3z mRNA expres- 
sion preceded the induction of the IFN-fl mRNA. The induc- 
tion levels of the ISGF37 mRNA after NDV infection were 
essentially the same in wild type and IRF-l-deficient EFs (data 
not shown). As shown in Fig. 2B, ISGF3y mRNA was induced 
by NDV infection even in the presence of a protein synthesis 
inhibitor, cycloheximide (CHX). This result indicates that 
ISGF37 mRNA induction is mediated irectly by the virus, 
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Fig. 1. The deduced amino acid sequence of mouse ISGF3), and the comparison with the sequence of human ISGF37 [16]. Identical residues are 
marked by bars ([), and residues that are conservative substitutions are marked by asterisks (*). 
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Fig. 2. (A) Expression of IFN-/Y and ISGF37 mRNA induced by NDV 
infection. (B) Expression of ISGF3y mRNA after the infection or 
mock-infection fNDV in the presence or absence of CHX (100/~g/ml). 
Total RNA was extracted at the indicated times, and 5 mg of RNA was 
subjected to RNA blotting analysis. Every filter was reprobed with the 
~-actin probe to confirm the RNA content in each slot. 
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rather than indirectly, e.g. by virus-induced IFNs. The expres- 
sion level of IFN-fl  mRNA was dramatically decreased in the 
presence of CHX (25-fold; data not shown), an observation 
consistent with the idea that the induction of ISGF3y expres- 
sion is a prerequisite vent for maximal IFN-fl gene induction. 
Next we tried to detect he activity of ISGF3y in cell extracts 
after viral infection by EMSA using an ISRE sequence as a 
probe. As shown in Fig. 3A, infection with NDV induced 1SRE 
binding activity in dKO-EF  extracts. With HeLa cells, we also 
detected the induction of binding activity with similar mobility 
following NDV infection. Addition of an anti- ISGF3y serum 
resulted in the disappearance of two bands; the lower of which 
Fig. 3. (A) Induction oflSGF3y and ISGF3 activities by NDV infection 
as detected by an ISRE probe. Proteins or extracts examined were as 
follows. Lanes: 1, no protein; 2, rabbit reticulocyte lysate (RRL); 
3, RRL programmed with human ISGF37 mRNA; 4, mock-infected 
IRF-dKO EFs; 5, IRF-dKO EFs 12 hours after NDV infection; 
6,mock-infected HeLa cells; 7-10, HeLa cells 8 hours after NDV infec- 
tion. In lane 8-10, extracts were preincubated with the following rabbit 
antisera. Lanes: 8, non-immune serum; 9, anti-ISGF37 serum [16]; 
10, a mixture of anti-IRF-1 and -IRF-2 sera [11]. (B) Enhancement of
ISGF3 activity in HeLa cell extract by the addition of in vitro translated 
ISGF37. The extract prepared as that used in lane 5 of (A) (lane 1) were 
supplemented with RRL (lane 2) or RRL programmed with human 
ISGF3y mRNA (lane 3 5). In lanes 4-5, proteins were preincubated 
with the non-immune rabbit serum (lane 4) or anti-ISGF3y serum. B 1 2 3 4 5 
<:3 ISGF3 
,<~ IRFs 
<::3 ISGF37 
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Fig. 4 (A) ISGF3y binds to the promoter element of the IFN-fl gene. 
Rabbit reticulocyte lysate (RRL) programmed with ISGF3? mRNA 
(lane 1) or after mixing with the extract of HeLa cells infected with 
NDV (lanes 2-5) were incubated with a promoter element of the IFN-fl 
gene (-95 to -54). In lanes 3~,, proteins were preincubated with the 
non-immune rabbit serum (lane 4) or anti-lSGF3y serum. In lane 5, a 
200-fold molar excess of cold A2 oligomer (a sequence which can bind 
to NF-kB [27]) was included in the binding reaction. (B) Competition 
EMSA. The binding of in vitro translated ISGF3T or IRF-1 to the 
radiolabeled probe (-95 to -63 of the IFN-fl gene promoter) were 
challenged by a 2000-fold molar excess of each cold competitor as 
depicted in the figure. 
we assume to be ISGF3y and the higher the ISGF3 complex 
containing ISGF37. The fact that addition of in vitro translated 
ISGF3? into the HeLa cell extract enhanced the activity of 
ISGF3 (Fig. 3B), due to the presence of pre-existing ISGF3 
components in this cell as described in [22] further verifies this 
assignment. Since the anti-ISGF3y serum available do not 
cross-react with mouse proteins, we were not able to conduct 
a similar analysis using IRF-dKO EFs, but we observed that 
complexes of similar mobilities appeared using extracts from 
NDV-infected IRF-dKO EFs. Thus both ISGF3y and ISGF3 
complex binding activities are induced by NDV infection in 
HeLa and IRF-dKO cells. Addition of anti-IRF sera resulted 
in the inhibition of a band of intermediate mobility. This band 
is absent in the IRF-dKO EFs lane and therefore presumably 
corresponds to IRF-1 and IRF-2. 
Collectively, these results prompted us to further pursue the 
possibility that ISGF3y and/or the ISGF3 complex may be a 
candidate(s) for the putative factor involved in IFN-fl gene 
induction. In fact, extensive sequence similarity has been noted 
previously between one virus-inducible element in the IFN-fl 
gene promoter and the ISREs of IFN-inducible genes [7]. 
3.2. ISGF37/ can bind to the IFN-fl promoter 
We next tested whether ISGF3y can bind to the IFN-fl pro- 
moter. EMSA was performed with the labeled oligonucleotide 
spanning the two IRF-Es and the NF-kB binding site in the 
IFN-fl promoter as a probe [8,24]. As shown in Fig. 4A, 
ISGF3y, produced by in vitro translation with rabbit reticulo- 
cyte lysate, formed a complex with the IFN-/J promoter se- 
quence. Although the affinity to this sequence is weaker than 
to ISRE by 20-fold (data not shown), these results indicate that 
ISGF3? has the potential to bind to the IFN-fl promoter. 
We then assessed the binding of the ISGF3 complex to the 
IFN-fl promoter sequence using HeLa cell extract supple- 
mented with in vitro translated ISGF3y. As shown in Fig. 4A, 
ISGF3? could bind to the probe under these conditions, how- 
ever ISGF3 complex was not detectable in this EMSA assay. 
Complexes with a similar mobility to ISGF3 complex are prob- 
ably NF-xB because they were competed out by excess 
amounts of cold xB sequence. Reconstituted ISGF3 made of 
in vitro translated ISGF3y and partially purified STATI/ 
STAT2 complex from HeLa cell extracts provided similar re- 
sults (data not shown). 
In an attempt to define the recognition sequence of ISGF3y 
in the IFN-fl promoter, we performed competition EMSA 
using a series of mutated versions of a region of the IFN-fl 
promoter containing two IRF-Es. As the labeled probe, we 
used a shortened version of the wild-type sequence containing 
only the two IRF-Es, which can still bind to ISGF3y, and as 
a protein source we used in vitro translated ISGF3y. As shown 
in Fig. 4B, sequences with mutations in the 3' half of IRF-E2 
region lost their ability to compete with the natural sequences 
for binding to ISGF3~,. In contrast, sequences with mutations 
in the 5" half of IRF-E2 region were still effective competitors 
with the natural sequence. These results suggest hat the 5' 
boundary required for the binding of ISGF3? is at least he -86 
or -85 nucleotides 5' to the start of the IFN-fl gene transcrip- 
tion. In contrast, all of the mutants could compete with the 
binding of in vitro translated IRF-1 to the natural sequence, 
consistent with previous findings that IRF-1 can bind to either 
the IRF-E1 or IRF-E2 element within the IFN-fl promoter [8]. 
In addition, one probe containing a mutation which causes 
decreased inducibility of the IFN-fl promoter by NDV (mutant 
E) [24] does not compete with ISGF3y, but does compete with 
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IRF-1 for binding to the natural promoter. This and the above 
results together support the idea that the sequence require- 
ments of ISGF3y and IRF-1 are different and that the binding 
of ISGF3y is important for the induction of the IFN-fl gene. 
4. Discussion 
In order to identify a factor(s) required for the IRF-l- inde- 
pendent pathway of IFN-J3 gene regulation, we performed PCR 
to clone other IRF-family members from IRF-dKO EFs in- 
duced to express IFN-fl mRNA. In this study, we were able to 
obtain only ISGF3y. Although the sequence of the ICSBP 
cDNA could justify its amplification by the PCR, this result 
was not seen, consistent with the fact that ICSBP is expressed 
only in lymphoid and macrophage cells [15]. 
In addition, we have shown by EMSA that ISGF3y can bind 
to the IRF-Es of the IFN-fl promoter. Significantly, the binding 
affinity is decreased by a mutation which reduces the inducibil- 
ity by NDV infection [24]. Taken together, these results indicate 
ISGF3y as an attractive candidate for the factor involved in the 
IRF-1 independent activation pathway of 1FN-fl gene tran- 
scription. If this is true, then ISGF3y is another factor which 
is involved in the regulation of both the IFN and IFN-inducible 
genes, a role which is reminiscent of that of IRF-1 [12,13,25]. 
In contrast to our results, it has been previously reported that 
ISGF3y cannot bind to the promoter element of the IFN-fl 
gene [16,26]. However the DNA probe used in that study 
spanned nucleotides -79 to -57 of the IFN-fl promoter and 
covered only the NF-kB binding site and IRF-E1. Our results 
from competition EMSA studies uggests that the 5' boundary 
required for the binding of ISGF3y is located at least 86 or 85 
nucleotides upstream of the transcription start site. 
It is known that ISGF3y is the main DNA binding subunit 
of the ISGF3 complex and that upon formation this complex 
displays higher affinity towards the ISRE than that of ISGF3)" 
alone [17]. At present, it is not clear whether ISGF3y functions 
on the IFN-fl promoter alone or in combination with other 
factors. Although our EMSA failed to detect he binding of the 
larger ISGF3 complex to the IFN-fl promoter, we cannot rule 
out the possibility that ISGF3 participates in the IFN-fl gene 
regulation. In addition, the possibility also exists that ISGF37 
may form a complex with proteins other than STAT1 and 2 in 
its regulation of the IFN-fl gene. 
Obviously, the best way to elucidate the functional role of 
ISGF37 in the regulation of the IFN-fl gene would be through 
a gene knock-out study. We are now in the process of produc- 
ing mice with disrupted ISGF37 alleles. 
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